Disc Medicine Inc (IRON)
41.62
-4.85
(-10.44%)
USD |
NASDAQ |
Jul 02, 16:00
43.69
+2.07
(+4.97%)
After-Hours: 20:00
Disc Medicine Cash from Financing (Quarterly): 15.90M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 15.90M |
| December 31, 2023 | 7.758M |
| September 30, 2023 | 0.46M |
| June 30, 2023 | 153.86M |
| March 31, 2023 | 77.31M |
| December 31, 2022 | 148.82M |
| September 30, 2022 | 0.022M |
| June 30, 2022 | 0.086M |
| March 31, 2022 | 0.055M |
| Date | Value |
|---|---|
| December 31, 2021 | -102.73M |
| September 30, 2021 | -1.25M |
| June 30, 2021 | -1.581M |
| March 31, 2021 | 195.49M |
| December 31, 2020 | 0.141M |
| September 30, 2020 | 14.00M |
| June 30, 2020 | 0.009M |
| March 31, 2020 | 20.09M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-102.73M
Minimum
Dec 2021
195.49M
Maximum
Mar 2021
31.08M
Average
0.46M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 1.043M |
| Alnylam Pharmaceuticals Inc | 28.91M |
| Marinus Pharmaceuticals Inc | 0.257M |
| Rocket Pharmaceuticals Inc | 1.184M |
| Regenxbio Inc | 120.72M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.60M |
| Cash from Investing (Quarterly) | -0.067M |
| Free Cash Flow | -71.72M |
| Free Cash Flow Per Share (Quarterly) | -1.357 |
| Free Cash Flow Yield | -7.26% |